Wunan Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wunan Zhou has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
- Nehal Nikhilesh Mehta
The George Washington University School of Medicine, Washington, D.C., USA
7 shared publications - Marcus Y. Chen
National Heart Lung and Blood Institute, NIH, Bethesda, MD, USA
6 shared publications - Alexander V. Sorokin
Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
5 shared publications - Martin Peter Playford
Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
5 shared publications - Sundus S. Lateef
Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
5 shared publications Amit K. Dey
National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
4 shared publications
Latest Publications
- 1 July 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (7) , 2030-2033.e1
Abdominal Visceral Adiposity Is Associated with Coronary Artery Plaque Lipid-Rich Necrotic Core Partly Mediated by Bone Marrow Uptake of 18F-FDG Positron Emission Tomography/Computed Tomography in Psoriasis
- 1 July 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (7) , 2030-2033.e1
Abdominal Visceral Adiposity Is Associated with Coronary Artery Plaque Lipid-Rich Necrotic Core Partly Mediated by Bone Marrow Uptake of 18F-FDG Positron Emission Tomography/Computed Tomography in Psoriasis
- 21 June 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (11) , 2909-2919
Association of S100A8/A9 with Lipid-Rich Necrotic Core and Treatment with Biologic Therapy in Patients with Psoriasis: Results from an Observational Cohort Study
- 21 June 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (11) , 2909-2919
Association of S100A8/A9 with Lipid-Rich Necrotic Core and Treatment with Biologic Therapy in Patients with Psoriasis: Results from an Observational Cohort Study
- 8 June 2022
- Published by Wiley in Clinical Cardiology
- Vol. 45 (6)
Cover Image: Volume 45 Issue 6
The cover image is based on the Full Article Inflammation, coronary plaque progression, and statin use: A secondary analysis of the Risk Stratification with Image Guidance of HMG CoA Reductase Inhibitor Therapy (RIGHT) study by Nehal N Mehta et al., https://doi.org/10.1002/clc.23808.
- 8 June 2022
- Published by Wiley in Clinical Cardiology
- Vol. 45 (6)
Cover Image: Volume 45 Issue 6
The cover image is based on the Full Article Inflammation, coronary plaque progression, and statin use: A secondary analysis of the Risk Stratification with Image Guidance of HMG CoA Reductase Inhibitor Therapy (RIGHT) study by Nehal N Mehta et al., https://doi.org/10.1002/clc.23808.
- Open Access
- 2 April 2022
- Published by Wiley in Clinical Cardiology
- Vol. 45 (6) , 622-628
Inflammation, coronary plaque progression, and statin use: A secondary analysis of the Risk Stratification with Image Guidance of HMG CoA Reductase Inhibitor Therapy (RIGHT) study
Background Statin treatment is a potent lipid-lowering therapy associated with decreased cardiovascular risk and mortality. Recent studies including the PARADIGM trial have demonstrated the impact of statins on promoting calcified coronary plaque. Hypothesis The degree of systemic inflammation impacts the amount of increase in coronary plaque calcification over 2 years of statin treatment. Methods A subgroup of 142 participants was analyzed from the Risk Stratification with Image Guidance of HMG CoA Reductase Inhibitor Therapy (RIGHT) study (NCT01212900), who were on statin treatment and underwent cardiac computed tomography angiography (CCTA) at baseline and 2-year follow-up. This cohort was stratified by baseline median levels of high-sensitivity hs-CRP and analyzed with linear regressions using Stata-17 (StataCorp). Results In the high versus low hs-CRP group, patients with higher baseline median hs-CRP had increased BMI (median [IQR]; 29 [27-31] vs. 27 [24-28]; p < .001), hypertension (59% vs. 41%; p = .03), and LDL-C levels (97 [77-113] vs. 87 [75-97] mg/dl; p = .01). After 2 years of statin treatment, the high hs-CRP group had significant increase in dense-calcified coronary burden versus the low hs-CRP group (1.27 vs. 0.32 mm(2) [100x]; p = .02), beyond adjustment (beta = .2; p = .03). Conclusions Statin treatment over 2 years associated with a significant increase in coronary calcification in patients with higher systemic inflammation, as measured by hs-CRP. These findings suggest that systemic inflammation plays a role in coronary calcification and further studies should be performed to better elucidate these findings.
- 2 April 2022
- Published by Wiley in Clinical Cardiology
- Vol. 45 (6) , 622-628
Open AccessInflammation, coronary plaque progression, and statin use: A secondary analysis of the Risk Stratification with Image Guidance of HMG CoA Reductase Inhibitor Therapy (RIGHT) study
Background Statin treatment is a potent lipid-lowering therapy associated with decreased cardiovascular risk and mortality. Recent studies including the PARADIGM trial have demonstrated the impact of statins on promoting calcified coronary plaque. Hypothesis The degree of systemic inflammation impacts the amount of increase in coronary plaque calcification over 2 years of statin treatment. Methods A subgroup of 142 participants was analyzed from the Risk Stratification with Image Guidance of HMG CoA Reductase Inhibitor Therapy (RIGHT) study (NCT01212900), who were on statin treatment and underwent cardiac computed tomography angiography (CCTA) at baseline and 2-year follow-up. This cohort was stratified by baseline median levels of high-sensitivity hs-CRP and analyzed with linear regressions using Stata-17 (StataCorp). Results In the high versus low hs-CRP group, patients with higher baseline median hs-CRP had increased BMI (median [IQR]; 29 [27-31] vs. 27 [24-28]; p < .001), hypertension (59% vs. 41%; p = .03), and LDL-C levels (97 [77-113] vs. 87 [75-97] mg/dl; p = .01). After 2 years of statin treatment, the high hs-CRP group had significant increase in dense-calcified coronary burden versus the low hs-CRP group (1.27 vs. 0.32 mm(2) [100x]; p = .02), beyond adjustment (beta = .2; p = .03). Conclusions Statin treatment over 2 years associated with a significant increase in coronary calcification in patients with higher systemic inflammation, as measured by hs-CRP. These findings suggest that systemic inflammation plays a role in coronary calcification and further studies should be performed to better elucidate these findings.
- 1 October 2021
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 14 (10) , 2044-2046
Sex Differences in Subclinical Coronary Atherosclerosis in Psoriasis by Coronary Computed Tomography Angiography
- 1 October 2021
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 14 (10) , 2044-2046
Sex Differences in Subclinical Coronary Atherosclerosis in Psoriasis by Coronary Computed Tomography Angiography
- 9 April 2021
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 96 (7) , 1812-1821
Relative Predictive Value of Circulating Immune Markers in US Adults Without Cardiovascular Disease: Implications for Risk Reclassification
- 9 April 2021
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 96 (7) , 1812-1821
Relative Predictive Value of Circulating Immune Markers in US Adults Without Cardiovascular Disease: Implications for Risk Reclassification
- 1 April 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (4) , 913-916
Impaired Coronary Blood Flow in Patients with Psoriasis: Findings from an Observational Cohort Study
- 1 April 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (4) , 913-916
Impaired Coronary Blood Flow in Patients with Psoriasis: Findings from an Observational Cohort Study
- 1 April 2021
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 28 (2) , 579-588
Coronary microvascular dysfunction, left ventricular remodeling, and clinical outcomes in aortic stenosis
- 1 April 2021
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 28 (2) , 579-588
Coronary microvascular dysfunction, left ventricular remodeling, and clinical outcomes in aortic stenosis
- Open Access
- 1 July 2020
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 41 (25) , 2366-2375
Hypertensive coronary microvascular dysfunction: a subclinical marker of end organ damage and heart failure
Hypertension is a well-established heart failure (HF) risk factor, especially in the context of adverse left ventricular (LV) remodelling. We aimed to use myocardial flow reserve (MFR) and global longitudinal strain (GLS), markers of subclinical microvascular and myocardial dysfunction, to refine hypertensive HF risk assessment. Consecutive patients undergoing symptom-prompted stress cardiac positron emission tomography (PET)-computed tomography and transthoracic echocardiogram within 90 days without reduced left ventricular ejection fraction (P = 0.034), including in the adaptive remodelling subset (adjusted HR 3.93, 95% CI 1.14–13.56, P = 0.030). We have demonstrated important associations between coronary microvascular dysfunction and myocardial mechanics that refine disease characterization and HF risk assessment of patients with hypertension based on subclinical target organ injury.
- 1 July 2020
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 41 (25) , 2366-2375
Open AccessHypertensive coronary microvascular dysfunction: a subclinical marker of end organ damage and heart failure
Hypertension is a well-established heart failure (HF) risk factor, especially in the context of adverse left ventricular (LV) remodelling. We aimed to use myocardial flow reserve (MFR) and global longitudinal strain (GLS), markers of subclinical microvascular and myocardial dysfunction, to refine hypertensive HF risk assessment. Consecutive patients undergoing symptom-prompted stress cardiac positron emission tomography (PET)-computed tomography and transthoracic echocardiogram within 90 days without reduced left ventricular ejection fraction (P = 0.034), including in the adaptive remodelling subset (adjusted HR 3.93, 95% CI 1.14–13.56, P = 0.030). We have demonstrated important associations between coronary microvascular dysfunction and myocardial mechanics that refine disease characterization and HF risk assessment of patients with hypertension based on subclinical target organ injury.